Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 22, 2025Canadian Hematology TodayOpen Access

Front-line Treatment for Chronic Lymphocytic Leukemia in 2025: Finite Duration Versus Continuous Treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

CAChathuri AbeyakoonAVAbi Vijenthira

Discussion

Loading...

Member takes

Overview

This review summarizes treatment outcomes of fixed-duration vs continuous therapy in chronic lymphocytic leukemia, emphasizing patient-centered decision-making.

Key Points

  • Fixed-duration therapy for chronic lymphocytic leukemia shows potential benefits over continuous treatment for certain patients.
  • Current Health Canada approvals include targeted treatments like venetoclax-obinutuzumab and Bruton’s tyrosine kinase inhibitors.
  • Evidence reviewed suggests that treatment selection might depend on patient-specific factors, including disease progression and toxicity.
  • Improvements in diagnostic techniques and targeted therapies have transformed chronic lymphocytic leukemia management in recent years.

Cite This Study

Abeyakoon et al. (2025) studied this question.

synapsesocial.com/papers/68d46fdc31b076d99fa6a56ahttps://doi.org/10.58931/cht.2025.4272
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis2024 · 23 citations
  2. 2First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial2024 · 34 citations
  3. 3Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial2021 · 671 citations
  4. 4Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia2022 · 491 citations
  5. 5Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study.2025 · 13 citations